Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine

Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations

(2015) Synnøve Eidem et al.   VACCINE

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

(2015) José Garcia-Sicilia et al.   Human Vaccines & Immunotherapeutics

Immunological persistence of a seasonal influenza vaccine in people more than 3 years old

(2015) Yunhua Bai et al.   Human Vaccines & Immunotherapeutics

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens

(2014) Nathalie Landry et al.   CLINICAL IMMUNOLOGY

A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response

(2014) Kawsar R. Talaat et al.   JOURNAL OF INFECTIOUS DISEASES

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

(2014) Brian J. Ward et al.   VACCINE

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers

(2014) Jenny G.H. Low et al.   VACCINE

A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination

(2014) Keith S Reisinger et al.   Human Vaccines & Immunotherapeutics

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

(2013) M. Safaeian et al.   Cancer Prevention Research

Combined Administration of MF59-Adjuvanted A/H5N1 Prepandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses 1 Year after a One-Dose Priming Schedule

(2013) Pio Lopez et al.   Clinical and Vaccine Immunology

Long-Term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine among Health Care Workers: Influence of Prior Seasonal Influenza Vaccination

(2013) Joon Young Song et al.   Clinical and Vaccine Immunology

Traditional and New Influenza Vaccines

(2013) S.-S. Wong et al.   CLINICAL MICROBIOLOGY REVIEWS

Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine

(2013) Pierre Van Damme et al.   Human Vaccines & Immunotherapeutics

Epidemiological Characterization of a Fourth Wave of Pandemic A/H1N1 Influenza in Mexico, Winter 2011–2012: Age Shift and Severity

(2012) Víctor H. Borja-Aburto et al.   ARCHIVES OF MEDICAL RESEARCH

Comparison of the Long-Term Immunogenicity of Two Pandemic Influenza A/H1N1 2009 Vaccines, the MF59-Adjuvanted and Unadjuvanted Vaccines, in Adults

(2012) Joon Young Song et al.   Clinical and Vaccine Immunology

An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

(2012) Paul Gillard et al.   Influenza and Other Respiratory Viruses

Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to

(2012) Joanne M. Langley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

(2012) G.-M. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects

(2012) Christoph Hatz et al.   VACCINE

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

(2012) Christoph Hatz et al.   VACCINE

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies

(2012) Elisa Faenzi et al.   VACCINE

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming

(2012) Maikel V.W. van der Velden et al.   VACCINE

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

(2012) Hideyuki Ikematsu et al.   Human Vaccines & Immunotherapeutics

Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine

(2012) Akihiko Saitoh et al.   Human Vaccines & Immunotherapeutics

Virus-like particle (VLP)-based vaccines for pandemic influenza

(2012) Constantino López-Macías   Human Vaccines & Immunotherapeutics

Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India

(2012) Babasaheb V. Tandale et al.   Human Vaccines & Immunotherapeutics

Immunogenicity, Boostability, and Sustainability of the Immune Response after Vaccination against Influenza A Virus (H1N1) 2009 in a Healthy Population

(2011) Elisabeth Huijskens et al.   Clinical and Vaccine Immunology

H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans

(2011) S. Khurana et al.   JOURNAL OF VIROLOGY

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

(2011) Constantino López-Macías et al.   VACCINE

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza

(2010) Nathalie Landry et al.   PLoS One

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

(2010) Subhashini Jagu et al.   VACCINE

Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence

(2010) Joon Young Song et al.   VACCINE

Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design

(2010) Emily M. Plummer et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

(2009) Marie-Pierre David et al.   GYNECOLOGIC ONCOLOGY

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

(2009) R. J. Garten et al.   SCIENCE

Immunosuppressive mechanisms in cancer: Consequences for the development of therapeutic vaccines

(2009) Stefanie Gross et al.   VACCINE

Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus

(2009) Gian Vincenzo Zuccotti et al.   VACCINE

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE

Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses

(2008) Sanae Sasaki et al.   PLoS One